Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v41-FR Version v29-EN
Language French English
Date Updated 2019-03-29 2019-02-20
Drug Identification Number 02216094 02216094
Brand name ZERIT - CAP 20MG ZERIT - CAP 20MG
Common or Proper name STAVUDINE STAVUDINE
Company Name BRISTOL-MYERS SQUIBB CANADA BRISTOL-MYERS SQUIBB CANADA
Ingredients STAVUDINE STAVUDINE
Strength(s) 20MG 20MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL
Packaging size 1 BTL x 60 1 BTL x 60
ATC code J05AF J05AF
ATC description DIRECT ACTING ANTIVIRALS DIRECT ACTING ANTIVIRALS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2019-03-25 2019-02-28
Actual start date
Estimated end date 2019-03-25 2019-03-12
Actual end date 2019-03-28
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Product on allocation Product on allocation
Health Canada comments